Search Results

Austin, Texas--(Newsfile Corp. - May 15, 2024) - Maxwell Biosciences, Inc, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides...

Austin, Texas--(Newsfile Corp. - May 8, 2024) - Maxwell Biosciences, a preclinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform...

Maxwell Biosciences (“Maxwell”), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors.

Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform

Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases.

Maxwell Biosciences (“Maxwell”), a preclinical drug discovery platform company focused on the development of synthetic compounds that mimic existing human biomolecules (biomimetic therapeutics) from our innate immune system, today announced the appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations.

Maxwell Biosciences announced the appointment of Kate McKinley and Douglas S. Boothe to its Board of Directors.

Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives.

Maxwell Biosciences to Present Data on CLAROMER TM Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference.